The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections: The ESTABLISH-1 Randomized Trial
Abstract
IMPORTANCE: Acute bacterial skin and skin structure infections (ABSSSIs), including cellulitis or erysipelas, major cutaneous abscesses, and wound infections, can be life-threatening and may require surgery and hospitalization. Increasingly, ABSSSIs are associated with drug-resistant pathogens, and many antimicrobial agents have adverse effects restricting their use. Tedizolid phosphate is a novel oxazolidinone in development for the treatment of ABSSSIs. OBJECTIVES: To establish the noninferiority of tedizolid phosphate vs linezolid in treating ABSSSIs and compare the safety of the 2 agents. DESIGN, SETTING, AND PATIENTS: The Efficacy and Safety of 6-day Oral Tedizolid in Acute Bacterial Skin and Skin Structure Infections vs 10-day Oral Linezolid Therapy (ESTABLISH-1) was a phase 3, randomized, double-blind, noninferiority trial that was conducted from August 2010 through September 2011 at 81 study centers in North America, Latin America, and Europe. The intent-to-treat analysis set consisted of data from 667 adults aged 18 years or older with ABSSSIs treated with tedizolid phosphate (n = 332) or linezolid (n = 335). INTERVENTIONS: A 200 mg once daily dose of oral tedizolid phosphate for 6 days or 600 mg of oral linezolid every 12 hours for 10 days. MAIN OUTCOME MEASURES: The primary efficacy outcome was early clinical response at the 48- to 72-hour assessment (no increase in lesion surface area from baseline and oral temperature of ≤37.6°C, confirmed by a second temperature measurement within 24 hours). A 10% noninferiority margin was predefined. RESULTS: In the intent-to-treat analysis set, the early clinical treatment response rates were 79.5% (95% CI, 74.8% to 83.7%) of 332 patients in the tedizolid phosphate group and 79.4% (95% CI, 74.7% to 83.6%) of 335 patients in the linezolid group (a treatment difference of 0.1% [95% CI, -6.1% to 6.2%]). The sustained clinical treatment response rates at the end of treatment (day 11) were 69.3% (95% CI, 64.0% to 74.2%) in the tedizolid phosphate group and 71.9% (95% CI, 66.8% to 76.7%) in the linezolid group (a treatment difference of -2.6% [95% CI, -9.6% to 4.2%]). Results of investigator-assessed clinical treatment success rates at a posttherapy evaluation visit (1-2 weeks after the end-of-treatment visit) were 85.5% (95% CI, 81.3% to 89.1%) in the tedizolid phosphate group and 86.0% (95% CI, 81.8% to 89.5%) in the linezolid group (a treatment difference of -0.5% [95% CI, -5.8% to 4.9%), and were similar for 178 patients with methicillin-resistant Staphylococcus aureus isolated from the primary lesion. CONCLUSIONS AND RELEVANCE: Tedizolid phosphate was a statistically noninferior treatment to linezolid in early clinical response at 48 to 72 hours after initiating therapy for an ABSSSI. Tedizolid phosphate may be a reasonable alternative to linezolid for treating ABSSSI. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01170221.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Klevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726
Comparative analysis of two rates
Miettinen, O., & Nurminen, M. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040211 · Cited by 1,110
Epidemiology of Methicillin‐Resistant Staphylococcus aureus
Boucher, H. W., & Corey, G. R. (2008) · Clinical Infectious Diseases · doi:10.1086/533590 · Cited by 805
Farrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
Vancomycin-Resistant Staphylococcus aureus in the United States, 2002-2006
Sievert, D. M., Rudrik, J. T., Patel, J. B., McDonald, L. C., Wilkins, M. J., & Hageman, J. C. (2008) · Clinical Infectious Diseases · doi:10.1086/527392 · Cited by 483
Morales, G., Picazo, J. J., Baos, E., Candel, F. J., Arribi, A., Peláez, B., Andrade, R., de la Torre, M., Fereres, J., & Sánchez‐García, M. (2010) · Clinical Infectious Diseases · doi:10.1086/650574 · Cited by 292
The oxazolidinones: past, present, and future
Shaw, K. J., & Barbachyn, M. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06330.x · Cited by 259
Optimally weighted, fixed sequence and gatekeeper multiple testing procedures
Westfall, P. H., & Krishen, A. (2001) · Journal of Statistical Planning and Inference · doi:10.1016/s0378-3758(01)00077-5 · Cited by 239
Corey, G. R., Wilcox, M., Talbot, G. H., Friedland, H. D., Baculik, T., Witherell, G. W., Critchley, I., Das, A. F., & Thye, D. (2010) · Clinical Infectious Diseases · doi:10.1086/655827 · Cited by 236
Self-citationReyes, J., Rincón, S., Díaz, L., Panesso, D., Contreras, G., Zurita, J., Carrillo, C., Rizzi, A., Guzmán, M., Adachi, J. A., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/648426 · Cited by 198
Shaw, K. J., Poppe, S., Schaadt, R., Brown-Driver, V., Finn, J., Pillar, C. M., Shinabarger, D., & Zurenko, G. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00859-08 · Cited by 181
Bishop, E. J., Melvani, S., Howden, B. P., Charles, P. G. P., & Grayson, M. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1599-1602.2006 · Cited by 146
Prokocimer, P., Bien, P. A., Surber, J., Mehra, P., DeAnda, C., Bulitta, J. B., & Corey, G. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00076-10 · Cited by 115
Self-citation(2009) · Emerging Infectious Diseases · doi:10.3201/eid1512.081341 · Cited by 102
Talbot, G. H., Powers, J. H., Fleming, T. R., Siuciak, J. A., Bradley, J. S., Boucher, H. W., & on behalf of the CABP-ABSSSI Project Team (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis566 · Cited by 84
Early Discharge of Infected Patients Through Appropriate Antibiotic Use
Eron, L. J., & Passos, S. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.1.61 · Cited by 80
Spellberg, B. J., Talbot, G. H., Boucher, H. W., Bradley, J. S., Gilbert, D. N., Scheld, W. M., Edwards, J. E., Bartlett, J. G., & Antimicrobial Availability Task Force of the Infectious Diseases Society of America (2009) · Clinical Infectious Diseases · doi:10.1086/600296 · Cited by 67
Covington, P. S., Davenport, J. M., Andrae, D. A., O’Riordan, W. D., Liverman, L. C., McIntyre, G., & Almenoff, J. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05044-11 · Cited by 39
Corey, G. R., & Stryjewski, M. E. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir162 · Cited by 38
Napolitano, L. M. (2008) · Surgical Infections · doi:10.1089/sur.2008.063.supp · Cited by 29
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Methicillin-resistant Staphylococcus aureus
Lee, A. S., de Lencastre, H., Garau, J., Kluytmans, J., Malhotra-Kumar, S., Peschel, A., & Harbarth, S. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.33 · Cited by 1,556
Raff, A. B., & Kroshinsky, D. (2016) · JAMA · doi:10.1001/jama.2016.8825 · Cited by 452
Antibiotics in the clinical pipeline in 2013
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.86 · Cited by 433
Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
Boucher, H. W., Wilcox, M., Talbot, G. H., Puttagunta, S., Das, A. F., & Dunne, M. W. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310480 · Cited by 432
Self-citation
Metadata
- Authors
- Prokocimer, P., De Anda, C., Fang, E., Mehra, P., & Das, A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-02-13
- Volume
- 309
- Issue
- 6
- Pages
- 559
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2039989497
- Cited by
- 361
- References
- 21
- FWCI
- 30.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.